Sigyn Therapeutics (SIGY) Current Deferred Revenue (2016 - 2018)

Sigyn Therapeutics (SIGY) posted Current Deferred Revenue of $20616.0 for Q3 2018, down 45.35% sequentially from $37726.0 in Q2 2018.

Sigyn Therapeutics (SIGY) Current Deferred Revenue (2016 - 2018) Analysis & Trends

Sigyn Therapeutics has reported Current Deferred Revenue for 3 years, with the latest figure at $20616.0 in Q3 2018.

Quarterly Current Deferred Revenue changed N/A year-over-year to $20616.0 in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $20616.0 (changed N/A YoY) and the FY2017 annual result came in at $81455.0, changed N/A from the prior year.
Current Deferred Revenue fell to $20616.0 in Q3 2018 per SIGY's latest filing, from $37726.0 in the prior quarter.
Over five years, Current Deferred Revenue peaked at $81455.0 in Q4 2017 and troughed at $20616.0 in Q3 2018.
A 3-year average of $50588.2 and a median of $43669.0 in 2017 frame the typical range for Current Deferred Revenue.
The sharpest annual moves came in 2017 and 2018: Current Deferred Revenue rose 3.34% in 2017, then declined 23.96% in 2018.
Over 3 years, Current Deferred Revenue stood at $78820.0 in 2016, then increased by 3.34% to $81455.0 in 2017, then plunged by 74.69% to $20616.0 in 2018.
According to Business Quant data, Current Deferred Revenue over the past three periods registered $20616.0, $37726.0, and $35300.0 for Q3 2018, Q2 2018, and Q1 2018 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Sigyn Therapeutics	48,161.31	-37,409.69	-

Download Data